

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

Health Technology Assessment (HTA)



IT Chini

im

m

0. Min

STATE DALLS

mann

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

"Values Talk" - A Tower of Babel¹

¬ Referral to many different and often incommensurate things...

- A key paradox:

The discourse about values is both very important and very ambiguous.

Stakeholders may be tempted to react to this problem with either

reductionism

(focusing on one particular definition of values to the neglect of other relevant types)

or

nihilism...

(either rejecting all values analyses as equally unreliable, or accepting all as equally credible)

used on a Canadian policy analysis by Mita Giacomini et al. (2004)

dkfz.

UNIVERSITÄT HEIDELBERG

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

"So why abandon an extended cost per QALY approach?"¹


¬ HTA is here to stay

- International practice of HTA has been heterogeneous (in particular w.r.t. the role of economic evaluation)
- Lack of compelling alternatives?
 - ¬ "MCDA may have a role in local decision-making, but still likely to use cost and QALYs"
- ¬ Can't measure all things anyway?
 - Yet formal evaluations need to reflect multiple criteria, in order to minimize degree of "taking into account"
- ¬ No single "right method" anyway?
- ¹J. Brazier (2017) [presentation to ISPOR Annual European Congress]
- Jurisdictions ["will"] vary on what they value in decision making attributes



ISPOR 20th Annual European Congress - Glasgow / Scotland - Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

From CUA to [Health-Related] Social "Utility"



UNIVERSITÄT HEIDELBERG

> ¹A. Gafni, S. Birch (1993) ²K. Claxton et al. (2013) ³M. Schlander et al. (2017)

ISPOR 20th Annual European Congress - Glasgow / Scotland - Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

Increasing Uneasiness with Thresholds

HTA Agencies

- ¬ NICE (England): end-of-life treatments, ultra-orphans
- TLV (Sweden): adjustments for severity

Research-Based Biopharmaceutical Industry

- Barriers to access
- Innovation (dealing with uncertainty and dynamic efficiency)

Payers

- ¬ NHS England: Cancer Drugs Fund
- ¬ A "prescription for uncontrolled growth in expenditures"1?

Academics

- ¬ Increasing literature on the importance of "other criteria"
- -Scientific foundations of actual benchmarks for cost effectiveness: might be too high2 / too low3 / non-existent4?

4when social preferences are taken into account dkfz.

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

Key Elements of the Conventional Logic

Use value: Quality-Adjusted Life Years (QALYs)

- ¬ (fully?) capture the value of health care interventions;
- ¬ are all created equal ("a QALY is a QALY is a QALY...").

Aggregation: Maximizing the number of QALYs produced

- ought to be the primary objective of collectively financed health schemes,
- ¬ leading to the concept of thresholds (or benchmarks) for the maximum allowed cost per QALY gained.

Decreasing cost per QALY

- implies increasing social desirability of an intervention.



dkfz.

UNIVERSITÄT HEIDELBERG

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

Loopholes of the Conventional Logic

Effectiveness and Efficiency

Need to justify the appropriateness of the chosen effectiveness criterion

- by definition, "efficiency" is a secondary or instrumental objective,
- ¬ whereas the "effectiveness" criterion invariably represents the primary objective.

Efficiency

Need to distinguish explicitly between

- technical efficiency, productive efficiency, and allocative efficiency;
- static and dynamic efficiency.

Social Value ("Utility")

Existence of

- components different from individual utility and its aggregation;
- ¬ social (and non-selfish) preferences; rights and duties.



ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

Valuation of Health: A Framing Issue?

- 1. Use value (consumer perspective)
- 2. Option value (due to uncertainty and risk averse citizens)
- 3. Externalities (caring externalities and altruistic behaviors)

Perspective on incremental costs and WTP:

- 1. direct out-of-pocket payments
- 2. private (voluntary) health insurance premiums
- 3. public (compulsory) health insurance premiums (or tax)

WTP_{direct_oop} ≤ WTP_{private_ins} ≤ WTP_{public_tax}

- But can we expect this additive relationship¹ to be (always) true?



dkfz.

UNIVERSITÄT HEIDELBERG

10

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

Economic Literature: Preferences for Health

Contingent Valuation (CV) of Health¹

- Smith and Sach identified 265 CV Studies (published from 1985 – 2005):
 - Focus on Use Value of Health only, 73%
 - Focus also on Option Value, 13%
 - Focus also on Externalities, 5%
 - Focus including Option Value and Externalities, 9%
- Arguably, Option Value and Externalities will be most important when access to high technology and/or costly interventions is at stake – *i.e., in practice, when most*
- Health Technology Assessments (HTAs) are conducted

1cf. R.D. Smith, T.C. Sach, Health Economics, Policy and Law 2010; 5: 91-111.

dkfz.

11

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

A Rapidly Growing Economic Literature

on a Broad Range of Characteristics¹

contributing to Social Value Judgments

- ¬ Attributes of the Health Condition
 - individual valuation of health conditions
 - ¬ severity of the condition
 - unmet medical need
 - urgency of an intervention
 - capacity to benefit from an intervention
- ¬ Attributes of the Persons Afflicted
 - non-discrimination (and claims-based approaches)
 - age (and fair innings)
 - other patient attributes
 - fairness objectives; aversion against all-or-nothing decisions

¹cf., for example, M. Schlander, S. Garattini, S. Holm, et al., Journal of Comparative Effectives Research 2014; 3 (4): 399-422.

dkfz.

UNIVERSITÄT HEIDELBERG

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

Social Preferences in the Economic Literature



ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

Research Need: "Social Preferences"

- ¬ many studies of social preferences ...
 - most of them small
 - limited in scope
 - likely to be impaired by framing effects
 - other study types (not choice-based experiments)
 - some studies of questionable methodology
- ¬ ... very difficult to generalize
 - severity probably best documented contextual variable
 - distinct difficulties to quantify effects observed
 - if measures of willingness-to-pay were incorporated, they typically reflected maximal individual WTP
 - social willingness-to-pay in exchange for health care programs covered under a collectively financed health scheme might be more relevant



dkfz.



*<u>·</u>

ESPM Project: Research Objectives

 To investigate systematically how the general public valuates selected characteristics ("attributes") of health care interventions,

ISPOR 20th Annual European Congress - Glasgow / Scotland - Nov. 07, 2017

Determining Value in Health Technology Assessment Consistent with Societal Aims

- n and how they weigh them against each other (including their interaction).
- To compare the valuation results obtained in the study with those based on the logic of cost effectiveness by means of a utility comparator.
- 3. To assess the sensitivity of weights to the level of information offered to respondents and to potential framing effects.

ESPM: "European Social Preferences Measurement" project: currently, project phase It (SoPHI study: "Societal Preferences for Health Care Interventions" in Switzerland is undergoing final evaluations, after completion of qualitative and quantitative pretests and of main DCE survey during 2017.

14

- 4. (in Phase II:) To identify international similarities and differences with regard to the valuation of the attributes tested.
- 5. (in Phase II:) to explore the agreement of respondents between their choices in the experimental setting, their policy implications, and their policy preferences.





ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

ESPM Project: Attributes Investigated

- 1. Severity of the initial health state: lost life expectancy (i.e., *ex ante*, before / without an intervention)
- 2. Severity of the initial health state: lost quality of life (i.e., *ex ante*, before / without an intervention)
- 3. Effectiveness of an intervention: life expectancy gained
- 4. Effectiveness of an intervention: quality of life gained
- 5. Age of patients (or "fair innings")
- 6. Rarity of disorder (i.e., prevalence or number of persons benefitting)
- Cost of intervention: perspective of a compulsory health scheme ("OKP"); payment vehicle = social willingness-to-pay





$\langle 0 \rangle$

ESPM Project: Design Elements

1. Representative population sample

¬ 1,501 respondents from Switzerland in Study Phase I

ISPOR 20th Annual European Congress - Glasgow / Scotland - Nov. 07, 2017

Determining Value in Health Technology Assessment Consistent with Societal Aims

- 2. Discrete Choice Experiment (DCE) design
- 3. Initial Preference Formation Phase
 - \neg prior to DCE experiment
- 4. Testing for framing effects (by randomization):
 - different levels of information on implications of rarity
 - ¬ information on cost per patient (either provided or withheld)
- 5. Perspective on costs:
 - ¬ incremental compulsory health insurance premiums
- 6. Utility comparator (with generic health state descriptions)
- 7. Econometric evaluation
 - incl. testing for interaction of attributes; subsamples, latent class, and random coefficient models

dkfz.

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

From CUA to MCDA and SCVA

SCVA: Social Cost Value Analysis

 Social WTP capturing the will to share health care resources¹ (option value and externalities)

Potential attributes influencing the will to share may include

- ¬ severity of the initial health state
- ¬ certain patient attributes
- ¬ a strong dislike for "all-or-nothing" resource allocation decisions
- ¬ **rights**-based considerations



dkfz.

UNIVERSITÄT HEIDELBERG

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

SCVA: How Different is it from CUA?

Moving from CUA to SCVA would be of little consequence, if and when

- the QALY calculation algorithm offered an adequate proxy for individual [health-related] utility gains,
 - ¬ including the transformation of length and quality of life inherent in the QALY model and further assumptions,
- individual [health-related] utility gains
 mapped into social [health-related] utility gains,
- citizens were not risk averse,
- ¬ citizens had little (if any) consideration for others,
 - which would eliminate any non-selfish preferences (for sharing health care resources),
- ¬ citizens' WTP was proportional to the number of patients benefitting from the adoption of a health care program.



ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

SCVA: A Changing Perspective

shifting the focus from cost per patient to cost at program level

- A decision-makers' (and payers') perspective has been traditionally overall budgetary impact (transfer cost)
- ¬ A social value perspective

(instead of a narrow focus on QALYs as a proxy for individual health-related "utility" and their aggregation) corresponds to social **opportunity cost** (or [social] value foregone) being reflected by net budgetary impact (*transfer cost*)

This reflects the type of decisions informed by HTAs,
 i.e., decisions on the adoption of health technologies
 at the level of programs (*not* at the level of individual patients)



UNIVERSITÄT HEIDELBERG

ISPOR 20th Annual European Congress – Glasgow / Scotland – Nov. 07, 2017 Determining Value in Health Technology Assessment Consistent with Societal Aims

Thank You for Your Attention!

Michael Schlander, M.D., Ph.D., M.B.A.

Contact

www.dkfz.de www.innoval-hc.com

m.schlander@dkfz.de michael.schlander@innoval-hc.com





Deutsches Krebsforschungszentrum (DKFZ) Im Neuenheimer Feld 581 (TP4) D-69120 Heidelberg INNOVAL^{HC} An der Ringkirche 4 D-65197 Wiesbaden +49 (0) 611 4080 789 0

Phone: +49 (0) 6221 42 1910

